Gå ubegrenset med Magzter GOLD

Gå ubegrenset med Magzter GOLD

Få ubegrenset tilgang til over 9000 magasiner, aviser og premiumhistorier for bare

$149.99
 
$74.99/År

Prøve GULL - Gratis

BIOTECH: Blood, Sweat and Tears

Newsweek Europe

|

February 14, 2025

Nine years in the making, Truvian's quick tabletop blood test promises to deliver where Theranos famously couldn't

- ALEXIS KAYSER

BIOTECH: Blood, Sweat and Tears

IN SEPTEMBER 2015, DR. DENA MARRINUCCI set out to perfect a tabletop device that could rapidly test a small amount of blood, returning results in under 30 minutes. If the concept sounds familiar, that's because it is. She wasn't the only one with ambitions to transform the laboratory industry.

The month after Marrinucci co-founded Truvian, The Wall Street Journal published an expose accusing Theranos-Truvian's now infamous, defunct competitor of misrepresenting the accuracy and reliability of its own blood-testing technology, while deceiving doctors, patients and investors. At the time, Theranos was valued at $9 billion.

The Journal's investigation set off a domino effect. Theranos lost its license and last summer its CEO, Elizabeth Holmes, began an 11-year prison sentence.

When Truvian launched in 2015, Marrinucci had six months of seed money from venture capiby tal firm Domain Associates and plans to raise a larger round quickly. But after the Theranos debacle, Truvian needed more than proof of concept. It needed proof of candor.

"We recruited some of the naysayers of Theranos, very high-profile opinion leaders in the laboratory medicine space," Marrinucci told Newsweek. "We said, let's bring them onto our team and learn from them and understand their skepticism, and have them help us review data from the very onset of the company." It took two years for Truvian to close its Series A funding round and begin refining its tabletop laboratory device. About six years and eight months later, I was rolling up my sleeve to test it out myself.

My Rapid Blood Test

I first met Marrinucci and Jay Srinivasan, Truvian's CEO, on September 6, 2024. They'd set up shop in a Chicago suite belonging to DNS Capital, one of Truvian's investors.

The FDA hadn't (and still hasn't) approved the company's platform, so I had to enroll in a "pilot study" before using it.

FLERE HISTORIER FRA Newsweek Europe

Newsweek Europe

Newsweek Europe

GATEN MATARAZZO

AS NETFLIX’S STRANGER THINGS COMES TO AN END, GATEN MATARAZZO, 23, IS focused on soaking in the final moments. “I really want to take it in and enjoy it. I don’t think I'll ever be in something that makes quite as much of an impact the way Stranger Things has.”

time to read

1 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

LEGACY IN MOTION

With the cameras rolling, King Charles celebrates a half-century of work redefining what royal duty means

time to read

7 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

AMERICA'S TOP FINANCIAL ADVISORY FIRMS 2026

FINANCIAL ADVISERS CAN HELP YOU MANAGE YOUR money, plan for retirement and create short- and long-term goals to keep you feeling financially secure for years to come.

time to read

4 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

Ultimate Warrior?

The team behind this android expects humanoid robots to be weaponized for military use. A demo at Newsweek’s HQ showed there is still a ways to go

time to read

12 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

STRUCK FROM HISTORY

Matthew Macfadyen talks exclusively to Newsweek about bringing a forgotten chapter of America's past to life in Netflix's Death by Lightning

time to read

6 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

TONATIUH

RARELY IN HOLLYWOOD DOES ONE SEE A STAR BORN OVERNIGHT, BUT THAT'S what happened to Tonatiuh with Kiss of the Spider Woman.

time to read

1 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

Trump's Numbers Game

As living costs are seen to rise, the president's approval rating is falling—mirroring backlash against Joe Biden

time to read

4 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

KING OF REHAB'S NEXT MISSION

He overcame addiction and opened the country's most prestigious treatment center. Now, Richard Taite is taking on America's fentanyl crisis

time to read

6 mins

November 28, 2025

Newsweek Europe

Newsweek Europe

AMERICA'S BEST HOME HEALTH AGENCIES 2026

A portrait of Sudani at a campaign event for the Reconstruction and Development Coalition list earlier this month, ahead of the parliamentary elections. Below: People attend a rally organized by the prime minister.

time to read

12 mins

November 21, 2025

Newsweek Europe

Newsweek Europe

Beijing Bytes Back

Blacklisted by Washington, Chinese tech firms have worked their way around U.S. curbs and are now ditching American chips for their own

time to read

6 mins

November 21, 2025

Listen

Translate

Share

-
+

Change font size